AMRA-MEDICAL
11.12.2018 12:30:06 CET | Business Wire | Press release
AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that it has received FDA clearance for AMRA® Profiler, now available for use in a clinical setting in the US. AMRA® Profiler is indicated for use as a magnetic resonance (MR) diagnostic device for non-invasive fat and muscle evaluation that enables the generation, display and review of MR-based body composition measurements.
AMRA is the first in the world to transform MR-images from a 6-minute whole-body MRI scan into 3D-volumetric fat and muscle measurements, enabling outstanding accuracy and precision when assessing volume and distribution of fat and muscles, as well as metabolic status.
“We are delighted with the FDA’s decision. The challenges facing healthcare systems across the world are well-documented. Cost constraints, together with societal issues such as obesity and an aging population, are putting hospitals and private clinics under increasing pressure, ” stated Eric Converse, CEO of AMRA.
“AMRA® Profiler helps address these challenges by providing physicians with the most detailed body composition assessment and imaging available, cost-effectively and with minimal intrusion to the patient. Ultimately this enables clinicians to make more informed treatment decisions about the whole body. This clearance is the next step in our journey of translating the benefits of AMRA into clinical practice and in ultimately contributing to the real world data and real world evidence that are playing an increasing role in health care decisions today .”
AMRA® Profiler provides a number of body composition measurements, such as visceral adipose tissue volume, subcutaneous adipose tissue volume, liver fat fraction, and thigh muscle volume, alongside associated medical images. These body composition measurements and images, when interpreted by a trained physician, may yield information that assists in diagnosis.
AMRA’s mission is to establish a new global standard in body composition analysis and confront global health challenges by enhancing the evidence base needed to predict and prevent disease.
-ENDS-
Notes to editor:
About AMRA:
AMRA is a ground-breaking, international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, delivering multiple fat and muscle biomarkers with unrivalled precision alongside contextual disease insights – all from a 6-minute whole-body MRI scan. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making, from clinical research to clinical care.
AMRA® Profiler precisely measures fat volumes, fat fractions, and lean tissue volumes - precise body composition measurement available as a decision support tool for use in clinical practice. AMRA® Profiler is also CE marked in Europe and available for clinical use in Sweden, UK and Germany.
For more information, visit www.amramedical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181211005392/en/
Contact:
AMRA Chelsea Ranger SVP Commercial & Market Strategy chelsea.ranger@amramedical.com MSL Rebecca Snazelle Director, Health +44 (0)7773 034 198 rebecca.snazelle@mslgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aarhus Vand Selects Netmore for Smart Meter Network25.8.2026 08:00:00 CEST | Press release
Partnership between Netmore, Aarhus Vand, and Kamstrup supports digitalization of metering network and water conservation across Aarhus Municipality, Denmark Netmore Group, the leading network operator and platform provider for Massive IoT, today announced a collaboration with Aarhus Vand and Kamstrup to support the deployment of approximately 69,000 digitally connected water meters across Aarhus Municipality, Denmark. Powered by Netmore's carrier-grade LoRaWAN® network and Kamstrup's digital water metering technology, the project will provide Aarhus Vand with real-time visibility into water consumption while helping residents better understand and reduce their water usage. Rollout begins in Tranbjerg following a successful pilot involving approximately 1,000 households, where the communication between Kamstrup's digital meters and Aarhus Vand was validated. The full deployment will continue through 2030, covering communities across Aarhus Municipality. The new water meters will elimin
Motorola Solutions fuldfører opkøbet af D-Fend Solutions25.8.2026 08:00:00 CEST | Pressemeddelelse
Beskyttelse af luftrummet for beredskabsmyndigheder og kritisk infrastruktur med differentieret, ikke-kinetisk RF-teknologi til cyberovertagelse Motorola Solutions (NYSE: MSI) har gennemført opkøbet af D-Fend Solutions (D-Fend), der er en førende virksomhed inden for anti-drone-teknologi, for en købspris på 1,5 mia. USD. Handlen giver beredskaber og erhvervsliv adgang til avancerede systemer til bekæmpelse af ubemandede luftfartøjer (C-UAS), der er udviklet til sikkert at neutralisere trusler fra uautoriserede droner. "Sikkerhed på jorden kræver sikkerhed i luften," siger Greg Brown, der er bestyrelsesformand og CEO i Motorola Solutions. "D-Fends gennemprøvede anti-drone-teknologi er et stærkt supplement til vores beredskabsløsninger og giver vores kunder verden over en differentieret beskyttelse af luftrummet." Præcis trusselsbegrænsning I modsætning til traditionelle anti-drone-metoder, der baserer sig på simpel detektion efterfulgt af jamming eller nedskydning, identificerer D-Fends
IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers25.8.2026 07:30:00 CEST | Press release
Research highlights emerging opportunities for food and beverage innovation IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF’s GLP-1 global consumer insights following the company’s 2025 GLP-1 Consumer Opportunity Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824816059/en/ “We are seeing that a change in appetite can lead to a broader change in the relationship people have with food, from how much consumers eat to how they choose, experience and participate in eating occasions,” said Harsch Koshti, regional marketing director, IFF Taste for Greater Asia. “For the food industry, this is a critical opportunity to listen closely to these emerging behaviors and think about h
Tigo Energy and Ingeteam Sign Certificate of Compatibility25.8.2026 06:00:00 CEST | Press release
Successful testing between Tigo MLPE and Ingeteam inverters validates an open ecosystem with proven compatibility for European solar installers. Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy solutions, today announced a Certificate of Compatibility with European energy technology leader, Ingeteam S.A., documenting which Ingeteam inverters and Tigo Flex MLPE products have passed compatibility testing. The certificate covers certain single-phase and three-phase INGECON® SUN products and members of the Tigo TS4 MLPE product family, when properly designed and installed. Together, these products are designed to deliver high-quality, enhanced value with a system that can generate and manage solar energy more efficiently and provide the features that solar energy customers in the residential, Commercial and Industrial (C&I) and Utility segments demand. Ingeteam, a leading decarbonization and energy transformation company building a sustainable future thr
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom